Amgen: The Red Gold and the Black Box

Discover how Amgen turned recombinant DNA into a multi-billion dollar empire, survived a massive safety crisis, and fought the FTC for its future.[INTRO]ALEX: In 1980, a group of scientists in California started a company that experimented with using genetics to make chickens grow faster and create better dye for blue jeans.JORDAN: Wait, they were trying to engineer better denim? That’s a far cry from a multi-billion dollar pharmaceutical giant.ALEX: It really is, but that company was Amgen, and they eventually pivoted to a project codenamed "Project Alpha." They successfully cloned a human gene that triggers the production of red blood cells, essentially creating a way to manufacture blood in a lab.JORDAN: That sounds like science fiction. So they went from blue jeans to literally printing life-saving proteins?[CHAPTER 1 - Origin]ALEX: Precisely. Amgen, which stands for Applied Molecular Genetics, was born during the wild west of the early biotech era. Their first CEO, George Rathmann, was a charismatic chemist who refused to let Amgen become just another boring drug company; he wanted to hunt for "blockbusters."JORDAN: "Blockbusters" sounds like a movie industry term. What does that mean in the world of medicine?ALEX: In pharma, a blockbuster is a drug that generates over a billion dollars in annual sales. Amgen found theirs in 1983 when a scientist named Fu-Kuen Lin isolated the gene for erythropoietin, or EPO.JORDAN: EPO... I’ve heard of that in sports. Isn't that what cyclists use to cheat?ALEX: It is, because it boosts red blood cells, giving you more oxygen and endurance. But for patients with kidney failure who were dangerously anemic, it was a miracle that meant they didn't need constant blood transfusions anymore.JORDAN: So they have the miracle gene. Was it smooth sailing from there?ALEX: Not even close. Amgen spent the late 80s locked in a brutal "patent war" with Genentech, who had their own version of the protein. Amgen eventually won in court, securing a monopoly on the U.S. dialysis market that turned them into a household name in the investment world.[CHAPTER 2 - Core Story]ALEX: By the 90s, Amgen was the king of biotech. They released Epogen and then Neupogen, which helps cancer patients fight off infections after chemo. These two drugs were like money-printing machines.JORDAN: Okay, but usually when a company is that successful, something goes wrong. Is there a catch?ALEX: The catch came in the mid-2000s, and it almost sank the company. Amgen had pushed a longer-acting version of the drug called Aranesp, but new studies suddenly linked high doses of these anemia drugs to increased risks of heart attacks, strokes, and even faster tumor growth.JORDAN: Wait, the drugs meant to help cancer patients were actually making their tumors grow faster?ALEX: In some cases, yes. It was a massive safety crisis. The FDA slapped a "black box" warning—their most severe caution—on the labels in 2007.JORDAN: I’m guessing investors panicked. How do you recover from a "black box" warning on your best-selling product?ALEX: You pivot. Hard. Amgen realized they couldn't rely on just two or three miracle drugs anymore. They started buying their way into new fields.JORDAN: They went on a shopping spree?ALEX: A massive one. They spent sixteen billion dollars to buy Immunex to get into immunology. Later, they spent ten billion on Onyx for cancer drugs. They were essentially reinventing themselves every decade to stay ahead of the lawsuits and the competition.JORDAN: Did they ever get back to that "miracle science" they started with, or did they just become a giant holding company?ALEX: They did both. In 2020, they achieved a scientific breakthrough with a drug called Lumakras. For forty years, scientists thought a specific cancer-causing protein called KRAS was "undruggable"—literally impossible to target—but Amgen finally cracked the code.[CHAPTER 3 - Why It Matters]JORDAN: So they're back to being the science pioneers. But with drug prices being such a hot topic, how is a giant like Amgen viewed today?ALEX: It's complicated. They are currently a leader in "biosimilars," which are basically generic versions of complex biologic drugs. They’re trying to lower costs while also defending their own high prices on older drugs.JORDAN: It sounds like they are fighting a war on two fronts: trying to be the innovator and the cost-cutter at the same time.ALEX: Exactly. And the government is watching closely. In 2023, the FTC tried to block Amgen's twenty-eight billion dollar purchase of Horizon Therapeutics. The government was worried Amgen would use its massive portfolio to bully insurance companies into favoring their new rare-disease drugs.JORDAN: Twenty-eight billion? That’s a huge bet on rare diseases. Did the deal go through?ALEX: It did, but only after Amgen promised not to use those "strong-arm" tactics. It shows that even for a pioneer, the rules of the game have changed. They aren't just a startup in a garage anymore; they are a central pillar of the global healthcare infrastructure.[OUTRO]JORDAN: This company has survived patent wars, a safety meltdown, and the FTC. What’s the one thing to remember about Amgen?ALEX: Amgen proved that you could turn the building blocks of life into a global industry, but their story shows that being a pioneer means you'll eventually have to answer for the risks of that innovation.JORDAN: That’s Wikipodia — every story, on demand. Search your next topic at wikipodia.ai.